Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.

Date publication

février 2024

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LEROUX Agnès , Pr MARCHAL Frédéric

Tous les auteurs :
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Quenet F, Marchal F, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38341381

Résumé

Ovarian pseudomyxoma peritonei (OPMP) are rare, without well-defined therapeutic guidelines. We aimed to evaluate cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat OPMP.

Mots clés

Cytoreduction, HIPEC, Mucinous tumor from teratoma, Ovarian carcinoma, Ovarian pseudomyxoma, Peritoneal pseudomyxoma

Référence

Ann Surg Oncol. 2024 02 10;: